|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Osteoporosis | |||||
| Osteopenia | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Bone Diseases, Metabolic | |||||
| Osteoporosis, Postmenopausal | |||||
| 3 | More general conditions related to this trial | ||||
| Bone Diseases | |||||
| Musculoskeletal Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Alendronate 70mg | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Alendronate | |||||
| 6 | More general drug interventions related to this trial | ||||
| Bone Density Conservation Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 7 | Sponsors listed in this trial | ||||
| University of Chicago | |||||
| National Institutes of Health (NIH) | |||||